Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled CHF 6333 in Healthy Males
NCT03056326Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) and Non-cystic fibrosis bronchiectasis (NCFB) comparing CHF6333 Active with Placebo (2 arms). Primary endpoints: Adverse events, Change in Vital signs and 8 more. Started Nov 2016; status: completed.
02
Drugs
CHF-6333
03
Conditions
cystic fibrosis (CF)Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT03056326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056326.